| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.09 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.09 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |